FDA-Approved Medications for Alzheimer’s Disease (2027 Guide)

Share this Article:

Entering 2027, Alzheimer's care has firmly moved from simple symptom management into a true disease-modifying era. For decades, families had access only to medications that temporarily masked memory loss and confusion.

Today, FDA-approved therapies target the disease's underlying biology by clearing toxic amyloid plaques from the brain, while newer options offer safer relief for agitation and sleep issues.

Approved medications for Alzheimer's Disease - And what's coming soon.

Although there is still no cure, earlier blood-based diagnostics and at-home treatment options are giving families more meaningful, independent time together. This updated guide covers every FDA-approved Alzheimer's medication available in 2027 and what is next in clinical trials.

Quick Guide: 2027 Alzheimer's Medications

  • Disease-Modifying Therapies: Leqembi (now available as an at-home autoinjector via LEQEMBI IQLIK) and Kisunla slow early-stage progression by clearing amyloid plaques.
  • Symptomatic Support: Aricept, Exelon, Razadyne, Zunveyl, Namenda, and Namzaric help manage memory and thinking across mild to severe stages.
  • Behavioral & Sleep Relief: Auvelity (approved April 2026 as the first non-antipsychotic for agitation), Rexulti, and Belsomra target agitation and insomnia.
  • Medicare Coverage: Traditional Medicare covers approved anti-amyloid drugs for eligible early-stage patients when doctors participate in a qualifying registry.

How Has Diagnosing Alzheimer's Disease Changed for 2027?

In 2027, diagnosing Alzheimer's disease relies on proactive biological testing rather than waiting for severe memory loss to appear. Doctors now use highly accurate blood tests and amyloid PET scans to detect toxic brain proteins early. This allows patients to receive a diagnosis during Mild Cognitive Impairment, when disease-modifying treatments work best.

In the past, physicians diagnosed dementia mostly by observing symptoms and ruling out other medical conditions. Today, biomarker tools give families clearer answers much sooner:

  • Advanced Blood Tests: Simple blood draws can now detect key Alzheimer's biomarkers, often reducing the need for invasive spinal taps.
  • Amyloid PET Scans: Specialized brain imaging allows neurologists to confirm the exact plaque buildup targeted by drugs like Leqembi and Kisunla.
  • Earlier Intervention: Identifying mild cognitive impairment early gives families access to the narrow window where plaque-clearing therapies are most effective.

Which FDA-Approved Medications Slow Alzheimer's Progression?

Two FDA-approved disease-modifying therapies, Leqembi and Kisunla, slow cognitive decline by removing amyloid plaques from the brain. Both are approved strictly for people in the early stages of Alzheimer's disease, including Mild Cognitive Impairment and mild dementia. They do not cure Alzheimer's, and both require routine brain MRI scans to monitor for side effects.

1. Leqembi (lecanemab-irmb)

Originally approved as a biweekly IV infusion, Leqembi expanded its at-home convenience significantly. Following its August 2025 weekly subcutaneous maintenance approval, the FDA approved LEQEMBI IQLIK in July 2026 as the first at-home subcutaneous starting dose. Eligible patients can now start and continue treatment at home using an autoinjector instead of traveling to an infusion center.

2. Kisunla (donanemab-azbt)

Approved in July 2024, Kisunla is a monthly IV infusion that targets amyloid plaques. A major practical benefit for caregivers is its finite treatment design: once follow-up brain scans confirm that plaques have been sufficiently cleared, doctors can stop the infusions.

3. Aduhelm (aducanumab)

Although Aduhelm was the first anti-amyloid drug approved, its manufacturer voluntarily withdrew it from the market in 2024. It is no longer prescribed.

Safety Note: Anti-amyloid drugs carry a risk of ARIA (Amyloid-Related Imaging Abnormalities), which involves temporary brain swelling or tiny bleeds. Regular MRI monitoring and genetic testing are essential parts of treatment.

What Symptomatic Medications Help With Memory and Thinking?

Symptomatic Alzheimer's medications do not stop the disease from progressing, but they help brain cells communicate more effectively to support daily memory, focus, and thinking. Doctors prescribe cholinesterase inhibitors for mild to moderate stages, glutamate regulators for moderate to severe stages, or combination capsules to simplify daily pill routines.

Cholinesterase Inhibitors (Mild to Moderate Stages)

  • Aricept (donepezil): An oral pill approved for all stages of Alzheimer's disease.
  • Exelon (rivastigmine): Available as an oral capsule or a daily skin patch, which can help older adults who have trouble swallowing pills.
  • Razadyne (galantamine): An oral medication used for mild-to-moderate dementia.
  • Zunveyl (benzgalantamine): A newer oral option approved for mild-to-moderate dementia, designed to cause fewer stomach side effects.

Glutamate Regulators (Moderate to Severe Stages)

  • Namenda (memantine): Helps regulate glutamate, a brain chemical involved in learning and memory processing.

Combination Therapy

  • Namzaric: Combines donepezil and memantine into a single daily capsule for moderate-to-severe Alzheimer's, reducing pill burden for caregivers.

Which Medications Treat Alzheimer's Agitation and Sleep Issues?

Managing behavioral symptoms is just as important as supporting memory. Three FDA-approved medications specifically target challenging Alzheimer's behaviors: Auvelity and Rexulti treat dementia-related agitation, while Belsomra treats insomnia. Treating these symptoms directly helps protect caregiver well-being and keeps loved ones safer at home.

1. Auvelity (dextromethorphan-bupropion)

In April 2026, the FDA approved Auvelity (previously studied as AXS-05) as the first non-antipsychotic oral medication for agitation associated with Alzheimer's dementia. Because it avoids the traditional antipsychotic drug class, it offers a welcome new option for families concerned about heavy sedation or antipsychotic risks.

2. Rexulti (brexpiprazole)

Rexulti is an atypical antipsychotic oral pill specifically approved to reduce agitation in Alzheimer's dementia. Like all antipsychotics in older adults with dementia, it carries a boxed warning and requires close physician supervision.

3. Belsomra (suvorexant)

Belsomra is an oral sleep aid FDA-approved to treat insomnia in people with mild-to-moderate Alzheimer's disease, helping reduce nighttime wandering and caregiver exhaustion.

Summary of FDA-Approved Alzheimer's Medications (2027)

Drug Name Medication Class Approved Stage / Use Real-World Benefit
Leqembi Disease-Modifying Early Stage (MCI / Mild) Slows decline; now available as an at-home autoinjector (LEQEMBI IQLIK).
Kisunla Disease-Modifying Early Stage (MCI / Mild) Monthly IV infusion that patients can stop once amyloid plaques clear.
Aricept / Exelon / Razadyne / Zunveyl Cholinesterase Inhibitors Mild to Moderate (Aricept: All) Supports daily memory and thinking; Exelon offers a convenient skin patch.
Namenda / Namzaric Glutamate Regulator / Combo Moderate to Severe Stabilizes attention and daily function; Namzaric combines two pills into one.
Auvelity Non-Antipsychotic Agitation in Alzheimer's First FDA-approved non-antipsychotic option for managing severe agitation.
Rexulti Atypical Antipsychotic Agitation in Alzheimer's Helps calm persistent agitation when behavioral strategies are not enough.
Belsomra Sleep Aid Insomnia in Mild-to-Moderate AD Improves sleep duration and reduces nighttime wandering.

What Promising Alzheimer's Drugs Are in 2027 Clinical Trials?

Several next-generation Alzheimer's drugs are advancing through Phase 3 clinical trials in 2027. Researchers are focusing on easier once-daily oral pills, subcutaneous self-injections, and “brain shuttle” technology designed to clear plaques with far lower risk of brain swelling. Results from major trials like Buntanetap and Remternetug are expected between 2027 and 2028.

Caregivers should also know that not every high-profile trial succeeds. For example, semaglutide (the active ingredient in Ozempic and Wegovy) did not meet its primary goals in the Phase 3 EVOKE and EVOKE+ Alzheimer's trials, and its extension was discontinued. Meanwhile, the drugs below represent the most active late-stage pipeline heading into 2027:

Promising Alzheimer's Medications in Phase 3 Clinical Trials

Drug Name Target / Purpose 2027 Status & Real-World Potential
Buntanetap Triple-Pathway Oral Pill Targets amyloid, tau, and alpha-synuclein. Phase 3 symptomatic results expected March 2027; 18-month data in 2028.
AR1001 (Mirodenafil) Oral Disease Modifier Once-daily pill. Late 2026 Phase 3 data showed mixed overall results, but slowed decline by 31% in monotherapy patients with no ARIA.
Remternetug Amyloid Clearance Eli Lilly's next-generation successor to Kisunla, being studied in Phase 3 (TRAILRUNNER-ALZ 3) as a subcutaneous self-injection.
Trontinemab “Brain Shuttle” Antibody Engineered to cross the blood-brain barrier efficiently with very low ARIA rates. Phase 3 TRONTIER results expected in 2028.

How Do Doctors Monitor Safety for Disease-Modifying Therapies?

Patients taking anti-amyloid drugs like Leqembi or Kisunla must follow strict safety protocols to catch ARIA (brain swelling or small bleeds) early. Before starting therapy, doctors recommend APOE4 genetic testing and a baseline MRI scan, followed by scheduled MRIs and routine neurological check-ins during the first several months of treatment.

Safety Monitoring for Anti-Amyloid Therapies

Monitoring Requirement Purpose Typical Schedule
Periodic MRI Scans Detects ARIA (brain swelling or microbleeds), which often cause no obvious symptoms. Before starting therapy and at set intervals during the first several months.
APOE4 Genetic Testing Evaluates ARIA risk; people with two copies of the APOE4 gene face higher risk. Recommended once before starting treatment.
Neurological Assessments Checks for side effects such as headache, sudden confusion, vision changes, or dizziness. Performed during routine follow-ups and infusion visits.

Does Medicare Cover the Newest Alzheimer's Medications?

Traditional Medicare covers FDA-approved disease-modifying Alzheimer's drugs like Leqembi and Kisunla for eligible early-stage patients, provided the prescribing doctor participates in a qualifying patient registry. However, families should budget for out-of-pocket coinsurance, infusion center fees, diagnostic amyloid PET scans, and required MRI monitoring unless a Medigap or Medicare Advantage plan covers them.

Under Medicare's coverage rules, Part B generally pays 80% of approved costs once you meet the annual deductible, leaving the remaining 20% to you or your supplemental insurance. Always ask your neurologist's billing office for a full cost estimate before starting treatment.

How Can You Spot Alzheimer's Treatment Scams?

No over-the-counter supplement, vitamin, or herbal remedy can cure or reverse Alzheimer's disease. Caregivers should be wary of any product claiming to “restore memory” or “melt away brain plaques.” Always check with your loved one's doctor before starting supplements, as unproven products can waste money and dangerously interact with prescription medications.

The National Institute on Aging recommends relying strictly on FDA-approved therapies and registered clinical trials rather than unregulated online remedies.

What Questions Should You Ask the Doctor?

Bringing a focused list of questions to your next neurology appointment helps you weigh each medication's real-world benefits against its risks and costs. Ask about disease stage eligibility, APOE4 genetic testing, at-home autoinjector options, how to measure if symptomatic drugs are working, and when to safely stop treatment.

Questions to Ask Your Doctor Checklist

  • ☐ Stage Eligibility: Is my loved one at the right stage (MCI or mild dementia) for a disease-modifying therapy like Leqembi or Kisunla?
  • ☐ Safety & ARIA Risk: Should we complete APOE4 genetic testing, and how often will MRI scans be required?
  • ☐ At-Home Convenience: Are we eligible for the LEQEMBI IQLIK at-home autoinjector instead of clinic infusions?
  • ☐ Behavioral Support: If agitation is an issue, is the non-antipsychotic option Auvelity appropriate for them?
  • ☐ Long-Term Plan: How will we measure whether symptomatic drugs are working, and when should we consider stopping them?

VIDEO: FDA Approved Alzheimer's Drugs For 2027 Signal a Turning Point

Frequently Asked Questions

Do the newest Alzheimer's medications cure the disease?

No, there is currently no cure for Alzheimer's disease. However, FDA-approved disease-modifying therapies like Leqembi and Kisunla remove amyloid plaques from the brain and can slow cognitive decline when started in the early stages.

Can Leqembi be taken at home now?

Yes. Following FDA approval of LEQEMBI IQLIK in July 2026, eligible patients can now both start and maintain Leqembi at home using a subcutaneous autoinjector rather than visiting an infusion center.

What is the difference between Aricept and Leqembi?

Aricept (donepezil) is a symptomatic medication that temporarily helps brain cells communicate to manage memory loss, but it does not slow the disease. Leqembi is a disease-modifying therapy that clears amyloid plaques to slow the underlying progression of Alzheimer's.

What is the newest FDA-approved drug for Alzheimer's agitation?

Auvelity (dextromethorphan-bupropion) was approved by the FDA in April 2026 as the first non-antipsychotic oral medication for agitation associated with Alzheimer's dementia.

Can someone in the late stages of Alzheimer's take Leqembi or Kisunla?

No. Disease-modifying therapies like Leqembi and Kisunla are approved strictly for people with Mild Cognitive Impairment (MCI) or mild dementia. They are not approved or effective for moderate or severe Alzheimer's.

Conclusion: Modern Alzheimer's Treatments Provide Hope

Navigating an Alzheimer's diagnosis is exhausting, and keeping up with rapid changes in FDA-approved treatments adds another layer of stress to your caregiving plate. While 2027 brings genuine breakthroughs like at-home anti-amyloid injections and non-antipsychotic agitation relief, every medication still carries a unique balance of benefits, costs, and safety risks.

Bring the checklist above to your next neurology visit, ask direct questions about Medicare coverage and monitoring, and partner with your medical team to build a realistic plan centered on your loved one's quality of life.

Recommended Internal Links:

Medical Disclaimer: The information provided on DailyCaring is for educational and informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Alzheimer's disease medications carry specific risks, including brain swelling and bleeding. Always consult directly with a neurologist or primary care physician to determine whether a specific medication or clinical trial is safe and appropriate for your loved one.

About the Author

Connie Chow is the Founder of DailyCaring.com.
Founder, DailyCaring.com

Connie is the founder of DailyCaring.com and was a hands-on caregiver for her grandmother for 20 years. (Grandma made it to 101 years old!) She knows how challenging, overwhelming, and all-consuming caring for an older adult can be. She also understands the importance of support, especially in the form of practical solutions, valuable resources, and self-care tips.

Subscribe
Notify of
2 Comments
Newest
Oldest
Bob
7 years ago

So appreciative of your web site ! We are entering into the latter stage of dementia and difficulty in the administration of medications. I will consult with her Doctor to see which of them we can consider cease to use.
Again, my thanks
Just an Old Soldier

In this Article